Diabetes Insipidus

Categories: Endocrine diseases, Nephrological diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Diabetes Insipidus

MalaCards integrated aliases for Diabetes Insipidus:

Name: Diabetes Insipidus 12 74 29 6 42 43 15 71 32


External Ids:

Disease Ontology 12 DOID:9409
ICD9CM 34 253.5
MeSH 43 D003919
NCIt 49 C43263
SNOMED-CT 67 15771004
ICD10 32 E23.2
UMLS 71 C0011848

Summaries for Diabetes Insipidus

MedlinePlus : 42 Diabetes insipidus (DI) causes frequent urination. You become extremely thirsty, so you drink. Then you urinate. This cycle can keep you from sleeping or even make you wet the bed. Your body produces lots of urine that is almost all water. DI is different from diabetes mellitus (DM), which involves insulin problems and high blood sugar. The symptoms can be similar. However, DI is related to how your kidneys handle fluids. It's much less common than DM. Urine and blood tests can show which one you have. Usually, DI is caused by a problem with your pituitary gland or your kidneys. Treatment depends on the cause of the problem. Medicines can often help. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Diabetes Insipidus is related to wolfram syndrome 1 and wolfram syndrome. An important gene associated with Diabetes Insipidus is AVP (Arginine Vasopressin), and among its related pathways/superpathways are Peptide ligand-binding receptors and Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds. The drugs Dexmedetomidine and Hydrocortisone acetate have been mentioned in the context of this disorder. Affiliated tissues include pituitary, brain and kidney, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 74 Diabetes insipidus (DI) is a condition characterized by large amounts of dilute urine and increased... more...

Related Diseases for Diabetes Insipidus

Diseases in the Diabetes Insipidus family:

Hereditary Central Diabetes Insipidus Acquired Central Diabetes Insipidus

Diseases related to Diabetes Insipidus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 921)
# Related Disease Score Top Affiliating Genes
1 wolfram syndrome 1 34.2 WFS1 CISD2 AVP
2 wolfram syndrome 34.1 WFS1 INS CISD2 AVP
3 diabetes insipidus, neurohypophyseal 34.0 WFS1 PRL POMC OXT NPTX2 AVPR2
4 diabetes insipidus, nephrogenic, autosomal 33.2 SLC12A1 REN OXT CLCNKB CLCNKA AVPR2
5 hydronephrosis 31.3 WFS1 SLC12A1 REN AQP2
6 hypopituitarism 31.1 PRL POMC INS CRH
7 nephrogenic syndrome of inappropriate antidiuresis 31.0 AVPR2 AVP
8 secondary adrenal insufficiency 31.0 INS AVP
9 adenohypophysitis 30.9 PRL POMC
10 septooptic dysplasia 30.9 PRL POMC AVP
11 empty sella syndrome 30.9 PRL POMC INS
12 hyperprolactinemia 30.8 PRL POMC INS
13 hypoadrenalism 30.8 POMC CRH
14 pituitary hormone deficiency, combined, 2 30.7 PRL POMC INS CRH AVP
15 lung oat cell carcinoma 30.7 POMC AVP
16 pituitary apoplexy 30.6 PRL POMC INS AVP
17 pituitary gland disease 30.6 PRL POMC INS CRH AVP
18 polycystic kidney disease 30.6 REN AVPR2 AVP AQP2
19 chromophobe adenoma 30.5 PRL POMC
20 amenorrhea 30.5 PRL POMC INS CRH
21 hypoglycemia 30.5 PRL POMC INS CRH
22 bartter syndrome, type 1, antenatal 30.5 SLC12A1 AQP2
23 central pontine myelinolysis 30.4 AVPR2 AVP AQP2
24 acromegaly 30.4 PRL POMC INS CRH
25 acute adrenal insufficiency 30.3 REN POMC
26 hypoaldosteronism 30.3 REN POMC
27 idiopathic edema 30.2 INS AQP2
28 primary hyperparathyroidism 30.2 PRL POMC INS
29 hyperthyroidism 30.2 REN PRL POMC INS
30 bartter disease 30.1 SLC12A1 REN CLCNKB CLCNKA AVP AQP2
31 abducens nerve disease 30.1 PRL POMC
32 liver cirrhosis 30.1 REN AVP AQP2 AFP
33 pre-eclampsia 30.1 REN OXT INS CRH AFP
34 sheehan syndrome 30.1 PRL POMC INS CRH AVP
35 apparent mineralocorticoid excess 30.1 REN POMC CLCNKB
36 mental depression 30.0 POMC OXT CRH
37 impotence 30.0 PRL POMC OXT INS
38 chronic kidney disease 29.9 REN POMC INS AVP AQP2
39 ileus 29.9 POMC INS CRH
40 anovulation 29.9 PRL INS CRH
41 oligohydramnios 29.9 REN OXT AQP3 AFP
42 neurofibromatosis, type ii 29.8 PRL POMC INS
43 pheochromocytoma 29.8 REN PRL POMC OXT CRH
44 inappropriate adh syndrome 29.8 REN POMC OXT AVPR2 AVP AQP3
45 optic nerve disease 29.8 WFS1 NPTX2 CISD2
46 peripheral nervous system disease 29.8 WFS1 POMC NPTX2 INS
47 melancholia 29.7 PRL POMC CRH AVPR1B
48 hypokalemia 29.7 SLC12A1 REN POMC INS CRH CLCNKB
49 gitelman syndrome 29.7 SLC12A1 REN CLCNKB CLCNKA
50 adrenal adenoma 29.7 REN POMC INS CRH

Comorbidity relations with Diabetes Insipidus via Phenotypic Disease Network (PDN):

Acute Cystitis Diabetes Insipidus, Nephrogenic, Autosomal
Hypothyroidism Pituitary Hormone Deficiency, Combined, 2

Graphical network of the top 20 diseases related to Diabetes Insipidus:

Diseases related to Diabetes Insipidus

Symptoms & Phenotypes for Diabetes Insipidus

MGI Mouse Phenotypes related to Diabetes Insipidus:

# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.39 AFP AQP2 AQP3 AVP AVPR1A AVPR1B
2 homeostasis/metabolism MP:0005376 10.28 AFP AQP2 AQP3 AVP AVPR1A AVPR1B
3 growth/size/body region MP:0005378 10.15 AQP2 AQP3 AVPR2 CISD2 CLCNKA CRH
4 endocrine/exocrine gland MP:0005379 10.1 AFP AVPR1A AVPR1B CISD2 CRH INS
5 mortality/aging MP:0010768 9.97 AFP AQP2 AQP3 AVP AVPR2 CISD2
6 integument MP:0010771 9.96 AQP2 AVPR2 CISD2 CRH INS OXT
7 nervous system MP:0003631 9.7 AVP AVPR1A AVPR1B CISD2 CRH INS
8 renal/urinary system MP:0005367 9.44 AQP2 AQP3 AVP AVPR2 CISD2 CLCNKA

Drugs & Therapeutics for Diabetes Insipidus

Drugs for Diabetes Insipidus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 121)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
Tolvaptan Approved Phase 4 150683-30-0 216237
6 Analgesics Phase 4
7 Anti-Inflammatory Agents Phase 4
8 Analgesics, Non-Narcotic Phase 4
9 Adrenergic Agents Phase 4
10 Hydrocortisone hemisuccinate Phase 4
11 Adrenergic Agonists Phase 4
12 Hydrocortisone-17-butyrate Phase 4
13 Hydrocortisone 17-butyrate 21-propionate Phase 4
14 Adrenergic alpha-2 Receptor Agonists Phase 4
15 Deamino Arginine Vasopressin Phase 4
16 Tranquilizing Agents Phase 4
17 Anti-Anxiety Agents Phase 4
18 Neurotransmitter Agents Phase 4
19 Hypnotics and Sedatives Phase 4
20 Anesthetics Phase 4
21 Adjuvants, Anesthesia Phase 4
22 GABA Agents Phase 4
23 Anesthetics, General Phase 4
24 Psychotropic Drugs Phase 4
25 Anesthetics, Intravenous Phase 4
26 GABA Modulators Phase 4
27 Central Nervous System Depressants Phase 4
28 Pharmaceutical Solutions Phase 4
29 Hormones Phase 4
30 diuretics Phase 4
31 Sodium Potassium Chloride Symporter Inhibitors Phase 4
Satavaptan Investigational Phase 3 185913-78-4 7029
33 Hormone Antagonists Phase 3
tannic acid Approved Phase 2 1401-55-4
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
Atorvastatin Approved Phase 2 134523-00-5 60823
Lithium carbonate Approved Phase 2 554-13-2
Dantrolene Approved, Investigational Phase 1, Phase 2 7261-97-4 2952 6914273
Dulaglutide Approved, Investigational Phase 2 923950-08-7
40 Hemostatics Phase 1, Phase 2
41 Vasoconstrictor Agents Phase 1, Phase 2
42 Natriuretic Agents Phase 1, Phase 2
43 Arginine Vasopressin Phase 1, Phase 2
44 Vasopressins Phase 1, Phase 2
45 Coagulants Phase 1, Phase 2
46 Hypoglycemic Agents Phase 2
47 Hypolipidemic Agents Phase 2
48 Anticholesteremic Agents Phase 2
49 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
50 Antimetabolites Phase 2

Interventional clinical trials:

(show top 50) (show all 91)
# Name Status NCT ID Phase Drugs
1 Effect of Dexmedetomidine as Anesthetic Coadjuvant on Plasmatic Cortisol Response in Transsphenoidal Surgery for Pituitary Tumors Unknown status NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
2 The Effect of Midazolam Premedication on Copeptine Concentration in Blood Completed NCT03474939 Phase 4 Midazolam Oral Tablet
3 Pilot Study of the Relationship of Ambient Copeptin to the Aquaretic Effects of Tolvaptan in Patients With Heart Failure Completed NCT01346072 Phase 4 tolvaptan
4 1-deamino 8-d-arginine Vasopressin in Percutaneous Ultrasound-guided Renal Biopsy: a Randomized Controlled Trial Completed NCT00748072 Phase 4 DDAVP;saline solution
5 Desmopressin in the Treatment of Mixed Nocturia With Nocturnal Polyuria and Low Nocturnal Bladder Capacity Completed NCT00902655 Phase 4 Desmopressin
6 Tolvaptan Treatment to Reverse Worsening Outpatient Heart Failure: Possible Role of Copeptin In Identifying Responders (TROUPER) Active, not recruiting NCT02476409 Phase 4 tolvaptan
7 Acute Heart Failure With High Copeptin Levels Treated With Tolvaptan Targets Increased AVP Activation for Treatment Efficacy Unknown status NCT01733134 Phase 3 Tolvaptan;placebo
8 A CLINICAL STUDY TO EVALUATE THE EFFICACY OF CAUSTICUM 200C IN THE TREATMENT OF PRIMARY ENURESIS Unknown status NCT02154152 Phase 3 Homoeopathic Medicine causticum 200c
9 Peroral Administration of Different Doses of Desmopressin Administered as a New Orally-Disintegrating Tablet and Desmopressin for Nasal Administration in the Treatment of CDI in Japanese Patients Completed NCT01280188 Phase 3 Desmopressin Oral Melt;Desmopressin intranasal
10 A Randomized, Double-Blind, Placebo-Group, Multicenter Study Evaluating the Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion Completed NCT00264927 Phase 3 SR121463B
11 An Open-Label, Multicenter Study Evaluating the Long-Term Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion Completed NCT00264914 Phase 3 SR121463B
12 A Multicenter, Uncontrolled, Open-label, Dose-titration Trial to Investigate the Efficacy and Safety of Tolvaptan Tablets in Patients With Hyponatremia in Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) Completed NCT03048747 Phase 3 Tolvaptan Oral Tablet
13 A Phase 1b, Multicenter, Pilot, Randomized, Double-blind Trial to Determine the Pharmacokinetics and Pharmacodynamics of Orally Administered Tolvaptan 3.75, 7.5, and 15 mg Tablets in Subjects With Syndrome of Inappropriate Antidiuretic Hormone Secretion Completed NCT02009878 Phase 1, Phase 2 tolvaptan
14 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation, Multicenter Study Evaluating the Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion. Completed NCT00032734 Phase 2 satavaptan (SR121463B)
15 Efficacy and Pharmacokinetics of Oral Thyroid Replacement Therapy in Organ Donors Completed NCT00238030 Phase 1, Phase 2 L-thryoxine;iv thryoxine
16 A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Dose Range Finding Study To Determine The Efficacy And Safety Of Fedovapagon In Men With Nocturia Completed NCT01656239 Phase 2 fedovapagon 1 mg;fedovapagon 2 mg;fedovapagon 4 mg;Placebo ( sugar pill)
17 AVERT Shock: Arginine Vasopressin During the Early Resuscitation of Traumatic Shock Completed NCT01611935 Phase 2 Vasopressin
18 Effects of Glucose Containing Fluid in the Treatment of Acute Dehydration Completed NCT01285713 Phase 2 5% Dextrose (D5) in Normal Saline (NS);Normal Saline (NS)
19 Atorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus: A Randomized Controlled Trial Recruiting NCT02967653 Phase 2 Atorvastatin
20 A Phase 1b Safety Trial of Dantronele Sodium in Pediatric and Adult Patients With Wolfram Syndrome Recruiting NCT02829268 Phase 1, Phase 2 dantrolene sodium
21 Effects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia: "The GOLD-Study" Recruiting NCT02770885 Phase 2 Dulaglutide;Placebo
22 The Influence of Vasopressin on Observational Learning of Placebo Analgesia Recruiting NCT03446456 Phase 1, Phase 2 Arginine vasopressin
23 A Randomised, Double-blind, Placebo-controlled, Five-way Cross-over Dose Response Study to Determine the Effect of VA106483 on Nocturnal Urine Volume in Elderly Male Subjects With Nocturia and Benign Prostatic Hypertrophy (BPH) Completed NCT01330927 Phase 1 VA106483
24 Use of Metformin to Treat Patients With Congenital Nephrogenic Diabetes Insipidus (NDI) Terminated NCT02460354 Phase 1 Metformin
25 Study of Novel Types of Familial Diabetes Insipidus Unknown status NCT00004364 desmopressin
26 GLP Analogs for Diabetes in Wolfram Syndrome Patients Unknown status NCT01302327 Exenatide
27 Evaluation of Copeptin in Patients With Cirrhosis and Ascites Unknown status NCT03318601
28 Diagnostic Utility of Copeptin in Addition to High-sensitivity Cardiac Troponin for the Early Diagnosis of Non-ST-Elevation Acute Coronary Syndromes - The COPACS Study Unknown status NCT01962506
30 Study of Prognostic Value of Copeptin for Myocardial Infarct Size and 6-month Prognosis in Patients With ST-elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: GOOD I Study Unknown status NCT03074214
31 Copeptin in the Diagnosis and Differential Diagnosis of Diabetes Insipidus. The CoSIP-Study Completed NCT00757276
32 Copeptin After Arginine Infusion for the Differential Diagnosis of the Polyuria-Polydipsia Syndrome ''The CARGO-Study'' Completed NCT01879137
33 Use of Copeptin in the Differential Diagnosis of Diabetes insipidus-a Prospective International Study Completed NCT01940614
34 Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus Completed NCT00004360 chlorothiazide
35 Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus Completed NCT00004363 chlorpropamide;desmopressin
36 Copeptin During a Standardized Psychological Stress Test Completed NCT01866137
37 Copeptin as a Diagnostic Marker in the Management of Neurosurgical Patients With Disturbance of Water Homeostasis Completed NCT01465672
38 Copeptin as a Stress Marker During a Written Examination - the CoEXAM Completed NCT02051647
39 GE DHM-AN-OR-2012/01 Completed NCT01648647
40 Copeptin During a Standardized Oral Glucose Tolerance Test and a Mixed Meal Tolerance Test Completed NCT01772914
41 Kinetics of Copeptin in Healthy Volunteers - a Prospective International Study Completed NCT02647736
42 The Circadian Rhythm of Copeptin Completed NCT02604875
43 Copeptin in Differentiation of Polyuria and Polydipsia Completed NCT01056887
44 Assessment of Circulating Copeptin Levels in Healthy Subjects and Patients With Renal Insufficiency After Oral Water Load and Hypertonic Saline Infusion Completed NCT00696605
45 Copeptin After an Oral Stimulation With Macimorelin in Healthy Volunteers - The Macicop-Study Completed NCT03844217 Macimorelin 0.5mg/kg body weight;Macimorelin 0.75mg/kg body weight
46 Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus Completed NCT00478335 sildenafil;calcitonin;hydrochlorothiazide/amiloride;indomethacin;Placebo for sildenafil;placebo for calcitonin
47 Vasopressin Deficiency in Hemorrhagic Shock Completed NCT01107314
48 Spectrum of Serum Sodium Disturbances in Patients With Non-sellar/Suprasellar Supratentorial Tumors Completed NCT03570203
49 The Influence of Water and Salt Intake on Copeptin Levels During Moderate Alcohol Consumption - a Pathophysiological Study Completed NCT03883503
50 Copeptin Registry (proCORE) Biomarkers in Cardiology (BIC)-19 Completed NCT02490969

Search NIH Clinical Center for Diabetes Insipidus

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Desmopressin Acetate
Vasopressin (USP)

Cochrane evidence based reviews: diabetes insipidus

Genetic Tests for Diabetes Insipidus

Genetic tests related to Diabetes Insipidus:

# Genetic test Affiliating Genes
1 Diabetes Insipidus 29

Anatomical Context for Diabetes Insipidus

MalaCards organs/tissues related to Diabetes Insipidus:

Pituitary, Brain, Kidney, Testes, Thyroid, Lung, Liver

Publications for Diabetes Insipidus

Articles related to Diabetes Insipidus:

(show top 50) (show all 8360)
# Title Authors PMID Year
Failure to thrive: the importance of measuring the electrolytes. 61 42
31630706 2019
Nephrogenic Diabetes Insipidus. 61 42
31588538 2019
Erdheim-chester disease revealed by diabetes insipidus. 61 42
31692902 2019
Intracranial Pure Germinoma With Optic Nerve Infiltration. 61
32040070 2020
An uncommon case of arthrogryposis, renal dysfunction, and cholestasis (ARC) syndrome and review of the renal involvement: Questions. 61
31463585 2020
Systematic review and practical guideline for the prevention and management of the renal side effects of lithium therapy. 61
31837914 2020
The effect of atorvastatin on cognition and mood in bipolar disorder and unipolar depression patients: A secondary analysis of a randomized controlled trial. 61
31733459 2020
Segregation of two variants suggests the presence of autosomal dominant and recessive forms of WFS1-related disease within the same family: expanding the phenotypic spectrum of Wolfram Syndrome. 61
31363008 2020
Adult craniopharyngioma: The role of extent of resection in tumor recurrence and long-term functional outcome. 61
32036264 2020
Pituitary Apoplexy Case Series: Outcomes Following Endoscopic Endonasal Transsphenoidal Surgery at a Single Tertiary Center. 61
32032792 2020
Sixty years single institutional experience with pediatric craniopharyngioma: between the past and the future. 61
31292757 2020
Sellar surprises: a single-centre experience of unusual sellar masses. 61
31910151 2020
Pituitary dysfunction in granulomatosis with polyangiitis. 61
31446541 2020
Rare occurrence of central diabetes insipidus with dermatomyositis in a young male. 61
32031964 2020
Endonasal endoscopic surgery for pediatric anterior cranial fossa encephaloceles: A systematic review. 61
32036168 2020
Predictive Factors, 30-Day Clinical Outcomes, and Costs Associated with Cerebrospinal Fluid Leak in Pituitary Adenoma Resection. 61
32021749 2020
Epidemiology, natural history, and optimal management of neurohypophyseal germ cell tumors. 61
32032947 2020
Diabetes Insipidus. 61
32005690 2020
Role of protein aggregation and degradation in autosomal dominant neurohypophyseal diabetes insipidus. 61
31785344 2020
Intravenous formulation of desmopressin delivered via oral and g tube routes for the treatment of central diabetes insipidus: First experience in infants. 61
31715009 2020
Systematic review and network meta-analysis assess the comparative efficacy and safety of transsphenoidal surgery for pituitary tumor. 61
32036504 2020
Orbitofrontal approach for the fenestration of a symptomatic sellar arachnoid cyst. 61
31966929 2020
Copeptin in the differential diagnosis of hypotonic polyuria. 61
31368050 2020
Diabetes insipidus - new concepts for diagnosis. 61
31986514 2020
Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series. 61
31950179 2020
A Rare Case of Intracranial Nongerminomatous Germ Cell Tumor in a 21-Year-Old Romanian Male. 61
31984143 2020
Pituitary tumors: epidemiology and clinical presentation spectrum. 61
31933100 2020
Time of peak nocturnal diuresis rate between men with secondary nocturnal polyuria versus nocturnal polyuria syndrome. 61
31961968 2020
Giant cell myocarditis with central diabetes insipidus: A case report. 61
31933698 2020
Neoplastic metastases to the endocrine glands. 61
31645015 2020
Transsphenoidal Surgery in Canines: Safety, Efficacy and Patient Selection. 61
32021832 2020
Clinical Situation, Therapy, and Follow-Up of Adult Craniopharyngioma. 61
31589293 2020
Sport-Related Concussion Preceding Adrenal Insufficiency and Hypopituitarism. 61
31913917 2020
Lessons from animal models of endocrine disorders caused by defects of protein folding in the secretory pathway. 61
31605742 2020
Nrf2 activation protects against lithium-induced nephrogenic diabetes insipidus. 61
31941842 2020
Epac1 null mice have nephrogenic diabetes insipidus with deficient corticopapillary osmotic gradient and weaker collecting duct tight junctions. 61
31943825 2020
Readmissions after endoscopic skull base surgery: associated risk factors and prevention. 61
31589814 2020
The neuroimaging features of Rathke's cleft cysts in children with endocrine-related diseases. 61
31670263 2020
Long-term hormone replacement treatment in a horse with central diabetes insipidus. 61
31960998 2020
Evaluation of pharmacochaperone-mediated rescue of mutant V2 receptor proteins. 61
31738937 2019
Post-obstructive Diuresis: A Cautionary Tale. 61
31938619 2019
Management of Hypopituitarism. 61
31817511 2019
A novel detrimental homozygous mutation in the WFS1 gene in two sisters from nonconsanguineous parents with untreated diabetes insipidus. 61
31893057 2019
Mutations in MAGEL2 and L1CAM Are Associated With Congenital Hypopituitarism and Arthrogryposis. 61
31504653 2019
Isolated Langerhans cell histiocytosis in the hypothalamic-pituitary region: a case report. 61
31856773 2019
Preservation of Hypothalamic Function with Endoscopic Endonasal Resection of Hypothalamus-Invaded Craniopharyngiomas. 61
31398519 2019
Childhood Langerhans cell histiocytosis: a disease with many faces. 61
31456157 2019
Clinicopathologic Characteristics and Endoscopic Surgical Outcomes of Symptomatic Rathke's Cleft Cysts. 61
31493602 2019
Imaging findings in hypophysitis: a review. 61
31863360 2019
Diabetes Insipidus After Discontinuation of Vasopressin Infusion for Treatment of Shock. 61
31567344 2019

Variations for Diabetes Insipidus

ClinVar genetic disease variations for Diabetes Insipidus:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MATN4 NM_003833.4(MATN4):c.515G>C (p.Gly172Ala)SNV Likely pathogenic 183295 rs730882210 20:43932996-43932996 20:45304356-45304356

Expression for Diabetes Insipidus

Search GEO for disease gene expression data for Diabetes Insipidus.

Pathways for Diabetes Insipidus

Pathways related to Diabetes Insipidus according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
3 12.3 WFS1 INS CISD2 AQP2
Show member pathways
Show member pathways
Show member pathways
8 11.49 PRL POMC AFP
10 10.57 AVPR2 AVP AQP3 AQP2
11 10.43 PRL POMC INS
12 10.21 POMC CRH

GO Terms for Diabetes Insipidus

Cellular components related to Diabetes Insipidus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 REN PRL POMC OXT INS CRH
2 secretory granule GO:0030141 9.33 POMC OXT AVP
3 extracellular region GO:0005576 9.28 REN PRL POMC OXT NPTX2 INS
4 endosome lumen GO:0031904 9.26 PRL INS

Biological processes related to Diabetes Insipidus according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.16 PRL POMC OXT INS CRH AVPR2
2 G protein-coupled receptor signaling pathway GO:0007186 10.1 POMC OXT INS CRH AVPR2 AVPR1B
3 positive regulation of cell proliferation GO:0008284 10.02 PRL INS CRH AVPR2 AVPR1A AVP
4 cellular protein metabolic process GO:0044267 9.95 WFS1 PRL INS AFP
5 positive regulation of cytosolic calcium ion concentration GO:0007204 9.88 OXT AVPR1B AVPR1A AVP
6 chloride transmembrane transport GO:1902476 9.84 SLC12A1 CLCNKB CLCNKA
7 female pregnancy GO:0007565 9.83 PRL OXT CRH
8 positive regulation of cell growth GO:0030307 9.83 INS AVPR1A AVP
9 social behavior GO:0035176 9.8 OXT AVPR1A AVP
10 cellular response to hormone stimulus GO:0032870 9.79 AVPR2 AVPR1B AVPR1A
11 generation of precursor metabolites and energy GO:0006091 9.79 POMC AVPR1A AVP
12 excretion GO:0007588 9.69 CLCNKB CLCNKA AVPR2
13 positive regulation of renal sodium excretion GO:0035815 9.66 OXT AVPR1A
14 positive regulation of glutamate secretion GO:0014049 9.65 AVPR1A AVP
15 positive regulation of blood pressure GO:0045777 9.65 OXT AVPR2 AVPR1A
16 drinking behavior GO:0042756 9.64 REN OXT
17 glycerol transport GO:0015793 9.64 AQP3 AQP2
18 hyperosmotic salinity response GO:0042538 9.63 OXT AVP
19 positive regulation of prostaglandin biosynthetic process GO:0031394 9.63 AVPR1A AVP
20 negative regulation of transmission of nerve impulse GO:0051970 9.61 AVPR1A AVP
21 water transport GO:0006833 9.61 AVP AQP3 AQP2
22 sperm ejaculation GO:0042713 9.6 OXT AVPR1A
23 negative regulation of urine volume GO:0035811 9.59 OXT AVPR2
24 response to ether GO:0045472 9.58 OXT CRH
25 grooming behavior GO:0007625 9.58 OXT AVPR1A AVP
26 positive regulation of cellular pH reduction GO:0032849 9.57 AVPR1A AVP
27 negative regulation of female receptivity GO:0007621 9.56 AVPR1A AVP
28 positive regulation of vasoconstriction GO:0045907 9.56 AVPR2 AVPR1B AVPR1A AVP
29 penile erection GO:0043084 9.54 AVPR1A AVP
30 maternal behavior GO:0042711 9.54 OXT AVPR1A AVP
31 cellular response to water deprivation GO:0042631 9.52 AVPR1A AQP2
32 positive regulation of systemic arterial blood pressure GO:0003084 9.5 AVPR2 AVPR1A AVP
33 regulation of systemic arterial blood pressure by vasopressin GO:0001992 9.33 AVPR2 AVPR1B AVPR1A
34 maternal aggressive behavior GO:0002125 9.13 OXT AVPR1A AVP
35 renal water homeostasis GO:0003091 9.02 WFS1 AVPR2 AVP AQP3 AQP2

Molecular functions related to Diabetes Insipidus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 9.5 OXT CRH AVP
2 insulin-like growth factor receptor binding GO:0005159 9.43 REN INS
3 water channel activity GO:0015250 9.4 AQP3 AQP2
4 voltage-gated chloride channel activity GO:0005247 9.37 CLCNKB CLCNKA
5 V1A vasopressin receptor binding GO:0031894 9.26 AVPR1A AVP
6 neurohypophyseal hormone activity GO:0005185 9.16 OXT AVP
7 vasopressin receptor activity GO:0005000 9.13 AVPR2 AVPR1B AVPR1A
8 hormone activity GO:0005179 9.1 PRL POMC OXT INS CRH AVP

Sources for Diabetes Insipidus

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....